UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Recommendations

Info

Committed to Advancing Development of Improved Cancer Therapies, Imaging Modalities, and Biomarkers As president of the UCSF Helen Diller Family Comprehensive Cancer Center, one of my key priorities is to initiate and advance programs that are developing new anticancer drugs making significant impact on helping cancer patients live longer and better lives. I recognize this goal is best accomplished by working in partnership with the broader life science industry. This searchable abstract book of UCSF research presented at ASCO is a resource for potential partners interested in identifying world-class faculty engaged in clinical oncology research. As an NCI-designated comprehensive cancer center, UCSF is recognized for our outstanding science, extensive resources, depth and breadth of our research in basic, clinical, and/or population sciences, as well as cutting edge research that bridges these scientific areas. Practically this means that our clinicians and basic scientists work closely together to (1) identify, develop and optimize novel therapeutics for biological efficacy and clinical utility, (2) assess tumor status and responsiveness to current therapies, (3) develop biomarkers for patient stratification and therapeutic response and (4) advance supportive care options to mitigate the toxicities associated with chemotherapy. Alan Ashworth, PhD, FRS President, UCSF Helen Diller Family Comprehensive Cancer Center Senior Vice President for Cancer Services, UCSF Health As is evident from the breadth and depth the research being presented at this year’s ASCO, UCSF is home to many of world’s finest oncology scientists and clinicians. I invite you learn more about our work and expertise by reaching out to our faculty. If you have any additional questions or need any assistance with your outreach, please contact the Director of Strategic Alliances for the Cancer Center: Cammie Edwards ( ). Wishing you a very productive meeting and we look forward to future discussions and collaborations. Professor of Medicine, Division of Hematology/ Oncology, Department of Medicine Alan Ashworth, PhD, FRS President, UCSF Helen Diller Family Comprehensive Cancer Center 2
HDFCCC Overview A Designated NCI Comprehensive Cancer Center Since 1999 The “comprehensive” designation—NCI’s highest ranking, awarded only after a rigorous evaluation process—recognizes UCSF’s excellence in basic research, clinical research, population based research, outreach and education, and our ability to integrate these diverse research approaches to cancer and turn them into clinical practice. Our Success is Driven by Our Faculty HDFCCC Membership: 397 Members & Associate Members 2 Nobel Laureates 3 Albert Lasker Award winners 8 Howard Hughes Medical Investigators 13 Members of the National Academy of Sciences 20 Members of the Institute of Medicine 18 Fellows of the American Academy of Arts and Sciences 4 Fellows of the Royal Society 3
Page 1: UCSF HELEN DILLER FAMILY COMPREHENS
Page 5 and 6: HDFCCC Overview Core Capabilities S
Page 7 and 8: Presentations Presentations View fu
Page 9 and 10: Presentations Phase II trials of ce
Page 11 and 12: Presentations CRS-207 immunotherapy
Page 13 and 14: Presentations Long-term OS for pati
Page 15 and 16: Presentations Randomized phase 2 st
Page 17 and 18: Presentations Genomic Profiling to
Page 19 and 20: Presentations Validating RNAseq-sig
Page 21 and 22: Presentations Phase I/II study of V
Page 23 and 24: Presentations Clinical and genomic
Page 25 and 26: Presentations IMAAGEN trial safety
Page 27 and 28: Presentations Immunogenicity of sip
Page 29 and 30: Presentations Pembrolizumab for adv
Page 31 and 32: Presentations Novel T cell exhausti
Page 33 and 34: Presentations Correlation between m
Page 35 and 36: Presentations ATLAS: A randomized,
Page 37 and 38: Presentations A prospective analysi
Page 39 and 40: Presentations Circulating Biomarker
Page 41 and 42: Presentations Extended follow-up re
Page 43 and 44: Presentations Adjuvant temozolomide
Page 45 and 46: Presentations Ribociclib (LEE011) a
Page 47 and 48: Presentations Androgen receptor (AR
Page 49 and 50: Presentations Efficacy and hematolo
Page 51 and 52: Presentations IMpassion130: a Phase
Page 53 and 54:
Presentations Randomized phase II t
Page 55 and 56:
Presentations Phase II trial with t
Page 57 and 58:
Presentations Academic and Communit
Page 59 and 60:
Presentations Prevention of everoli
Page 61 and 62:
Presentations A phase 2 randomized,
Page 63 and 64:
Presentations PD-L1 expression, Can
Page 65 and 66:
Presentations The Heart of the Matt
Page 67 and 68:
Presentations 4-year results of the
Page 69 and 70:
Presentations Impact of landmark re
Page 71 and 72:
Presentations Phase II study of ali
Page 73 and 74:
Presentations Can lay health worker
Page 75 and 76:
Presentations Medical Management of
Page 77 and 78:
Presentations Prospective evaluatio
Page 79 and 80:
Presentations A phase II randomized
Page 81 and 82:
Presentations Early, molecular dete
Page 83 and 84:
Presentations Metastatic melanoma,
Page 85 and 86:
Presentations Three-year overall su
Page 87 and 88:
Presentations Heritage: A phase III
Page 89 and 90:
Presentations Determining barriers
Page 91 and 92:
Presentations Controversies in Loca
Page 93 and 94:
Presentations A pharmacodynamic stu
Page 95 and 96:
Presentations Final results of a ph
Page 97 and 98:
Presentations Comparative performan
Page 99 and 100:
Presentations Identification of sym
show all

UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Create successful ePaper yourself

Delete template?

Save as template?